

Peer Review

Review of: "The Precision Oncology Approach to Molecular Cancer Therapeutics Targeting Oncogenic Signalling Pathways Is a Means to an End"

Hany Akeel Al-hussaniy¹

1. University of Baghdad, Iraq

This is a broad, well-organized narrative review that covers major oncogenic pathways, tumor heterogeneity, precision oncology concepts, and newer “omics + AI” themes; however, its main weakness is *insufficient critical depth and originality*: it reads largely as an encyclopedic overview with limited synthesis (no clear conceptual framework, no explicit inclusion/exclusion strategy, and few “so what?” take-home messages that reshape the field). The manuscript also overextends—many sections list pathways/targets at textbook length (e.g., long pathway descriptions, extensive kinase-inhibitor tables) without adequately discussing *clinical translation constraints* (actionability tiers, assay validity, confounders in biomarker use, resistance mechanisms in real-world settings, equity/cost/access, and how to prioritize targets across contexts). Methodologically, it lacks a transparent review method (databases searched, date limits, selection criteria), and several claims feel generalized or potentially outdated without anchoring to key recent trials or guidelines; additionally, tables need tightening (Table 2 is long and may be redundant; better to summarize by class, indication, and key resistance/toxicity notes), and the writing needs careful language editing (typos, spacing, occasional overstatements).

Declarations

Potential competing interests: No potential competing interests to declare.